Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. (Q53849156)

20 May 2018

title

Quantitative assessment of HIV-1 protease inhibitor interactions with drug efflux transporters in the blood-brain barrier. (English)

1 reference

20 May 2018

1 reference

Corbin J Bachmeier

1

1 reference

20 May 2018

Timothy J Spitzenberger

series ordinal

2

1 reference

20 May 2018

William F Elmquist

series ordinal

3

1 reference

20 May 2018

Donald W Miller

series ordinal

4

1 reference

20 May 2018

publication date

3 August 2005

1 reference

20 May 2018

published in

Pharmaceutical Research

1 reference

20 May 2018

volume

22

1 reference

20 May 2018

issue

8

1 reference

20 May 2018

page(s)

1259-1268

1 reference

20 May 2018

Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11095-005-5271-Y

A co-culture-based model of human blood-brain barrier: application to active transport of indinavir and in vivo-in vitro correlation

21 January 2018

1 reference

12 December 2020

Expression of various multidrug resistance-associated protein (MRP) homologues in brain microvessel endothelial cells

1 reference

12 December 2020

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

1 reference

12 December 2020

Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients

1 reference

12 December 2020

In vitro blood-brain barrier permeability of nevirapine compared to other HIV antiretroviral agents.

1 reference

12 December 2020

Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate

1 reference

12 December 2020

Anti-HIV drug distribution to the central nervous system

1 reference

12 December 2020

Current knowledge and future prospects for the use of HIV protease inhibitors

1 reference

12 December 2020

Interactions of HIV protease inhibitors with ATP-dependent drug export proteins

1 reference

12 December 2020

Effect of modulators on the ATPase activity and vanadate nucleotide trapping of human P-glycoprotein

1 reference

12 December 2020

Xenobiotic transport across isolated brain microvessels studied by confocal microscopy

1 reference

12 December 2020

Photometric microtiter assay of inorganic phosphate in the presence of acid-labile organic phosphates

1 reference

12 December 2020

Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.

1 reference

12 December 2020

Direct evidence that saquinavir is transported by multidrug resistance-associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2).

1 reference

12 December 2020

Pharmacokinetic enhancement of protease inhibitor therapy

1 reference

12 December 2020

The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells.

1 reference

12 December 2020

Plasma membrane localization of multidrug resistance-associated protein homologs in brain capillary endothelial cells

1 reference

12 December 2020

Rational use of in vitro P-glycoprotein assays in drug discovery

1 reference

12 December 2020

P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals

1 reference

12 December 2020

The protease inhibitor ritonavir inhibits the functional activity of the multidrug resistance related-protein 1 (MRP-1).

1 reference

12 December 2020

Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir

1 reference

12 December 2020

HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.

1 reference

12 December 2020

Differences in the intracellular accumulation of HIV protease inhibitors in vitro and the effect of active transport

1 reference

12 December 2020

HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2).

1 reference

12 December 2020

Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs

1 reference

12 December 2020

Blood-brain barrier efflux transport

1 reference

12 December 2020

Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters

1 reference

12 December 2020

GF120918, a P-glycoprotein modulator, increases the concentration of unbound amprenavir in the central nervous system in rats

1 reference

12 December 2020

Stimulation of P-glycoprotein-mediated drug transport by prazosin and progesterone. Evidence for a third drug-binding site.

1 reference

12 December 2020

Drug efflux transporters in the CNS.

1 reference

12 December 2020

P-Glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance?

1 reference

12 December 2020

Development of drug resistance to HIV-1 protease inhibitors

1 reference

12 December 2020

Expression of the human multidrug resistance cDNA in insect cells generates a high activity drug-stimulated membrane ATPase

1 reference

12 December 2020

Effects of a P-glycoprotein inhibitor on brain and plasma concentrations of anti-human immunodeficiency virus drugs administered in combination in rats

1 reference

12 December 2020

A fluorometric screening assay for drug efflux transporter activity in the blood-brain barrier

1 reference

12 December 2020

Transport of HIV protease inhibitors through the blood-brain barrier and interactions with the efflux proteins, P-glycoprotein and multidrug resistance proteins

1 reference

12 December 2020

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors

1 reference

12 December 2020

Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor.

1 reference

12 December 2020

Communication between multiple drug binding sites on P-glycoprotein

1 reference

12 December 2020

10.1007/S11095-005-5271-Y

Identifiers

DOI

1 reference

20 May 2018

1 reference

20 May 2018